Literature DB >> 17052484

Presence of p16 hypermethylation and Epstein-Barr virus infection in transplant-associated hematolymphoid neoplasm of the skin.

Jack L Arbiser1, Karen P Mann, Elizabeth M Losken, Cynthia Cohen, Kalpana Reddy, Kenneth Kokko, Brian Pollack, Chung-Yang Fan, Fiona O'Reilly.   

Abstract

BACKGROUND: Epstein-Barr virus (EBV) is associated with the malignant transformation of B, T, and NK lymphocytes in humans, especially in immunosuppressed individuals.
OBJECTIVE: We describe an unusual case confined to the skin in a 39-year-old African American female following a renal transplant.
METHODS: Morphologically and immunophenotypically, the tumor was best classified as a plasmablastic lymphoma; however, the neoplastic population revealed rearrangements of both immunoglobulin heavy chain (IgG) and T cell receptor gamma (TCR-gamma). In situ hybridization demonstrated the presence of Epstein-Barr early RNA species (EBER) in the lymphoma cells, consistent with EBV infection.
RESULTS: We have previously demonstrated that EBV-induced reactive oxygen is associated with hypermethylation of the tumor suppressor gene p16 in Burkitt lymphoma, and that p16 hypermethylation is nearly always associated with EBV infection in Burkitt lymphoma. LIMITATIONS: Further studies are needed to determine whether p16 is widely suppressed in immunosuppression-induced lymphoma.
CONCLUSION: In this study, we demonstrated high levels of hypermethylation of the tumor suppressor gene p16, thus supporting the role of EBV as a carcinogen in post-transplant lymphoproliferative disease.

Entities:  

Mesh:

Year:  2006        PMID: 17052484     DOI: 10.1016/j.jaad.2006.06.043

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  7 in total

Review 1.  The antioxidant paradox: what are antioxidants and how should they be used in a therapeutic context for cancer.

Authors:  Michael Y Bonner; Jack L Arbiser
Journal:  Future Med Chem       Date:  2014       Impact factor: 3.808

Review 2.  Plasmablastic Lymphoma: A Review of Current Knowledge and Future Directions.

Authors:  Ghaleb Elyamany; Eman Al Mussaed; Ali Matar Alzahrani
Journal:  Adv Hematol       Date:  2015-08-18

3.  Targeting the duality of cancer.

Authors:  Jack L Arbiser; Michael Y Bonner; Linda C Gilbert
Journal:  NPJ Precis Oncol       Date:  2017-06-22

4.  Honokiol inhibits ultraviolet radiation-induced immunosuppression through inhibition of ultraviolet-induced inflammation and DNA hypermethylation in mouse skin.

Authors:  Ram Prasad; Tripti Singh; Santosh K Katiyar
Journal:  Sci Rep       Date:  2017-05-10       Impact factor: 4.379

5.  Cutaneous plasmablastic lymphoma in an immunocompetent patient with long-term pyrimethamine use for essential thrombocythemia: a case report and literature review.

Authors:  Ing Soo Tiong; Magreet Strauss; Michael B Y Lau; Shingirai Chiruka
Journal:  Case Rep Hematol       Date:  2013-02-06

6.  Posttransplant lymphoproliferative disorders.

Authors:  Hazem A H Ibrahim; Kikkeri N Naresh
Journal:  Adv Hematol       Date:  2012-04-17

7.  Immunosuppression-associated primary cutaneous plasmablastic lymphoma secondary to romidepsin.

Authors:  Collin M Costello; Connor J Maly; Sam Snider; Kevin J Severson; David J DiCaudo; Allison C Rosenthal; Donald W Northfelt; William Rule; Fiona E Craig; Mark R Pittelkow; Aaron R Mangold
Journal:  JAAD Case Rep       Date:  2019-12-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.